Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV-06 in Inflammatory Knee Osteoarthritis
NCT04447898Phase 1Completed
- Sponsor
- Peptinov
- Start
- Feb 2021
- Primary completion
- Feb 2023
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PPV-06 in knee osteoarthritis (OA) (3 arms), sponsored by Peptinov. Primary endpoint: Dose Limiting Toxicity at 42 weeks. Started Feb 2021; status: completed.
02
Drugs
PPV-06
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04447898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447898.